4-day delay in tumor development in the combined treatment, lower reduction in body weight and cancer cachexia, serum and intestinal IL-18 and IFN-γ, appearance of infiltrating T, B and NK cells in the tumors. This evidence concerns the gene IL18 and neoplasm.